Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer
- 13 January 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (5), 884-895
- https://doi.org/10.1007/s00259-009-1351-2
Abstract
Salivary gland impairment following high activity radioiodine therapy of differentiated thyroid cancer (DTC) is a severe side effect. Dosimetric calculations using planar gamma camera scintigraphy (GCS) with 131I and ultrasonography (US) provided evidence that the average organ dose per administered 131I activity (ODpA) is too low to account for observed radiation damages to the salivary glands. The objective of this work was to re-estimate the ODpA using 124I PET(/CT) as a more reliable approach than 131I GCS/US. Ten DTC patients underwent a series of six (or seven) PET scans and one PET/CT scan after administration of ∼23 MBq 124I-iodide. Volumes of interest (VOIs) drawn on the CT and serial PET images were used to determine the glandular volumes and the imaged 124I activities. To enable identical VOIs to be drawn on serial PET images, each PET was co-registered with the CT image. To correct for partial volume effect and for the artificial bias in the activity concentration due to cascading gamma coincidences occurring in 124I decay, the imaged activity was effectively corrected using isovolume recovery coefficients (RCs) based on recovery phantom measurements. A head-neck phantom, which contained 124I-filled spheres, was manufactured to validate the isovolume recovery correction method with a realistic patient-based phantom geometry and for a range of activity concentration regimes. The mean±standard deviation (range) ODpA projected for 131I was calculated using the absorbed dose fraction method. The ODpAs (in Gy/GBq) for the submandibular and parotid glands were 0.32 ± 0.13 (0.18–0.55) and 0.31 ± 0.10 (0.13–0.46), respectively. No significant differences (p> 0.2) in the mean ODpA between 124I PET(/CT) and 131I GCS/US dosimetry was found. The validation experiment showed that the percentage deviations between RC-corrected and true activity concentrations were <10%. 124I PET(/CT) dosimetry also corroborates the low ODpAs to the salivary glands. A voxel-based calculation taking into account the nonuniform activity distributions in the glands is necessary to possibly explain the radiation-induced salivary gland damage.Keywords
This publication has 22 references indexed in Scilit:
- 124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic ComparisonJournal of Nuclear Medicine, 2009
- Optimized 124I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid CancerJournal of Nuclear Medicine, 2008
- Partial-Volume Effect in PET Tumor ImagingJournal of Nuclear Medicine, 2007
- Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancerNuclear Medicine Communications, 2006
- The Impact of PET and SPECT on Dosimetry for Targeted Radionuclide TherapyZeitschrift für Medizinische Physik, 2006
- An improved MCNP version of the NORMAN voxel phantom for dosimetry studiesPhysics in Medicine & Biology, 2005
- An Immunohistochemical Study of Na+/I−Symporter in Human Thyroid Tissues and Salivary Gland TissuesEndocrinology, 1998
- An Immunohistochemical Study of Na+/I- Symporter in Human Thyroid Tissues and Salivary Gland TissuesEndocrinology, 1998
- Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodineNuclear Medicine Communications, 1996
- Revised Average Geometric Factors for Cylinders in Isotope Dosage.Radiology, 1965